Market Place
Sourcing Support
Sandoz US launches generic paclitaxel in single-dose vial
11 Oct 2024 //
GLOBENEWSWIRE
Theriva Reaches VIRAGE Trial Enrollment For Pancreatic Cancer
23 Sep 2024 //
GLOBENEWSWIRE
Incyte`s Retifanlimab Extends PFS In Anal Carcinoma At ESMO 2024
14 Sep 2024 //
BUSINESSWIRE
Immuneering Reports Positive Phase 2a Data For IMM-1-104
12 Sep 2024 //
GLOBENEWSWIRE
CanariaBio Completes Enrollment For Oregovomab Phase 2 In Ovarian Cancer
23 Aug 2024 //
PR NEWSWIRE
Compass Therapeutics Completes Enrollment For CTX-009 Study
06 Aug 2024 //
GLOBENEWSWIRE
AstraZeneca`s breast cancer drug combination fails in late-stage trial
19 Jun 2024 //
REUTERS
AZ Imfinzi plus chemotherapy gets US nod for certain type of endometrial cancer
17 Jun 2024 //
REUTERS
US FDA grants fast track designation to Theriva Biologics’ VCN-01
27 May 2024 //
PHARMABIZ
Angle announces study of ovarian cancer CTCs using Parsortix system
18 May 2024 //
PHARMABIZ
Hutchmed in collab with Hengrui initiate phase II/III trial of surufatinib
16 May 2024 //
PHARMABIZ
Kexing Paclitaxel Plant Passes EU GMP Certification
10 May 2024 //
PR NEWSWIRE
Compass gets US FDA fast track for its bispecific DLL4/VEGF-A antibody, CTX-009
27 Apr 2024 //
PHARMABIZ
Compass Gets FDA Fast Track For CTX-009 + Pacli in Pre-Treated Biliary Cancer
25 Apr 2024 //
GLOBENEWSWIRE
Ratiopharm`s Pazenir (paclitaxel) Receives Approval in Europe
11 Jan 2024 //
EMA
GSK`s cancer drug combination meets primary goal in late-stage trial
19 Dec 2023 //
PRESS RELEASE
Adlai Nortye Announces Completion of Patient Enrollment in PIII of Buparlisib
17 Nov 2023 //
GLOBENEWSWIRE
Novocure Provides Update on Phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 Trial
28 Aug 2023 //
BUSINESSWIRE
BMS, BeiGene end legacy Celgene deal years after China ban
04 Aug 2023 //
FIERCE PHARMA
Pelareorep & Paclitaxel Induces Responses in Metastatic HR+/HER2– Breast Cancer
03 Jul 2023 //
ONCLIVE
Intra-arterial Gemcitabine Improves OS in Locally Advanced Pancreatic Cancer
30 Jun 2023 //
ONCLIVE
Journal of Clinical Oncology Publishes Results of Corcept™s Ph2 of Relacorilant
27 Jun 2023 //
GLOBENEWSWIRE
Puma Announces Presentation of Biomarker Findings from PII Study of Alisertib
04 Jun 2023 //
BUSINESSWIRE
Sustainable Production of Natural Substances by Plant Cell Cultivation
15 Mar 2023 //
PRESS RELEASE
Compass Announces that the PII Data of CTX-009 in Combination with Paclitaxel
19 Jan 2023 //
GLOBENEWSWIRE
Athenex Announces Quantum Leap Collaborative Reports +ve Trial Result of I-SPY2
20 Dec 2022 //
GLOBENEWSWIRE
Panbela Receives EMA Opinion on Orphan Designation for Ivospemin
14 Dec 2022 //
GLOBENEWSWIRE
Dragonfly Therapeutics Initiates Phase 2 Study of HER2 Targeting TriNKET DF1001
06 Dec 2022 //
PRNEWSWIRE
GSK’s Jemperli RUBY PIII trial met its primary endpoint for endometrial cancer
02 Dec 2022 //
PRESS RELEASE
AIM ImmunoTech Announces Presentation of New Data -Roswell Park Cancer Center
14 Nov 2022 //
GLOBENEWSWIRE
Abraxis Bioscience LLC Receives FDA Warning Letter
08 Nov 2022 //
FDA
Alembic Pharma gets USFDA nod for generic injection to treat cancer
27 Oct 2022 //
ECONOMICTIMES
Alembic`s Generic Paclitaxel Receives Approval in the U.S.
20 Oct 2022 //
FDA
Panbela Receives Approvals to Open Sites in Spain, France & Italy for SBP-101
30 Sep 2022 //
GLOBENEWSWIRE
NGM Bio Presents Updated Preliminary Findings from Ongoing P1b Trial of NGM120
13 Sep 2022 //
GLOBENEWSWIRE
Panbela Announces First Patient Enrolled in its Aspire Trial Studying SBP-101
11 Aug 2022 //
GLOBENEWSWIRE
Merck Provides Update on Phase 3 KEYNOTE-921
03 Aug 2022 //
BUSINESSWIRE
Athenex to publish Data from PIII Study Comparing Oral Paclitaxel + Encequidar
25 Jul 2022 //
GLOBENEWSWIRE
Innovent and Lilly Jointly Announce the Approval of TYVYT by China NMPA
20 Jun 2022 //
PRNEWSWIRE
Corcept Therapeutics to Start PIII Trial of Relacorilant Plus Nab-Paclitaxel
06 Jun 2022 //
GLOBENEWSWIRE
Junshi Nabs NMPA Approval of sNDA for Toripalimab plus Paclitaxel and Cisplatin
16 May 2022 //
GLOBENEWSWIRE
Compass Therapeutics Reports Positive Interim Phase 2 Data of CTX-009
04 May 2022 //
GLOBENEWSWIRE
What To Expect From Bristol Myers Squibb Stock After Q1 Results?
28 Apr 2022 //
FORBES
Relacorilant Plus Nab-Paclitaxel Extends Survival in Women with Ovarian Cancer
30 Mar 2022 //
GLOBENEWSWIRE
Adlai Nortye Advances Trial of Pelareorep-Paclitaxel Combo
24 Mar 2022 //
PRNEWSWIRE
NICE draft guidance does not recommend pembrolizumab plus chemo for TNBC
09 Mar 2022 //
PHARMAFILE
Well Begun, Half Done - SIRONA Randomized Trial Achieves 50% enrollment
09 Feb 2022 //
PRNEWSWIRE
CERP Celebrates 100 Peer-Reviewed Published Studies on Niagen
31 Jan 2022 //
BUSINESSWIRE
Microcap cancer player goes belly up after pancreatic tumor drug flops key study
27 Jan 2022 //
ENDPTS
Panbela Initiates ASPIRE Study of SBP-101 with Nab-Paclitaxel & Gemcitabine
26 Jan 2022 //
GLOBENEWSWIRE
Panbela Presents Clinical Data on Phase 1b Trial of SBP-101 in Metastatic PDA
24 Jan 2022 //
GLOBENEWSWIRE
Data From Pivotal Phase 3 Study of KEYTRUDA + LENVIMA in Endometrial Carcinoma
20 Jan 2022 //
BUSINESSWIRE
Pieris Pharma Announces First Patient Dosed Phase 2 Gastric Cancer
14 Jan 2022 //
TRIALSITENEWS
Encouraging Updated Data from Phase 2 MARIO-3 TNBC Trial Presented at 2021 SABCS
10 Dec 2021 //
BUSINESSWIRE
Gilead`s Immunomedics CMO exits to Aadi as it nears FDA decision
26 Oct 2021 //
FIERCEBIOTECH
Erytech`s eryaspase flunks late-stage pancreatic cancer trial; shares drop
26 Oct 2021 //
MARKETWATCH
OncXerna Announces New Biomarker Data from Retrospective Analysis of Results
23 Oct 2021 //
GLOBENEWSWIRE
Bristol Myers` Abraxane falls into shortage from manufacturing woes
20 Oct 2021 //
ENDPTS
Fierce Pharma Asia—Takeda`s cell, gene therapy deals; BMS-BeiGene Abraxane brawl
15 Oct 2021 //
FIERCEPHARMA
